Mostrar el registro sencillo del ítem

dc.contributor.authorBenítez Camacho, Josefa 
dc.contributor.authorBallesteros, Antonio
dc.contributor.authorBeltrán Camacho, Lucía 
dc.contributor.authorRojas Torres, Marta 
dc.contributor.authorRosal Vela, Antonio 
dc.contributor.authorJiménez Palomares, Margarita 
dc.contributor.authorSánchez Gomar, Ismael 
dc.contributor.authorDurán Ruiz, María del Carmen 
dc.contributor.otherAnatomía Patológica, Biología Celular, Histología, Historia de la Ciencia, Medicina Legal y Forense y Toxicologíaes_ES
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2024-03-14T12:20:29Z
dc.date.available2024-03-14T12:20:29Z
dc.date.issued2023-11-10
dc.identifier.issn1757-6512
dc.identifier.urihttp://hdl.handle.net/10498/31396
dc.description.abstractDiabetes mellitus (DM) constitutes a chronic metabolic disease characterized by elevated levels of blood glucose which can also lead to the so-called diabetic vascular complications (DVCs), responsible for most of the morbidity, hospitalizations and death registered in these patients. Currently, different approaches to prevent or reduce DM and its DVCs have focused on reducing blood sugar levels, cholesterol management or even changes in lifestyle habits. However, even the strictest glycaemic control strategies are not always sufficient to prevent the development of DVCs, which reflects the need to identify reliable biomarkers capable of predicting further vascular complications in diabetic patients. Endothelial progenitor cells (EPCs), widely known for their potential applications in cell therapy due to their regenerative properties, may be used as differential markers in DVCs, considering that the number and functionality of these cells are affected under the pathological environments related to DM. Besides, drugs commonly used with DM patients may influence the level or behaviour of EPCs as a pleiotropic effect that could finally be decisive in the prognosis of the disease. In the current review, we have analysed the relationship between diabetes and DVCs, focusing on the potential use of EPCs as biomarkers of diabetes progression towards the development of major vascular complications. Moreover, the effects of different drugs on the number and function of EPCs have been also addressed.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceStem Cell Research and Therapy. Vol. 14, nº 1, December 2023, 324es_ES
dc.subjectDiabetes mellituses_ES
dc.subjectDiabetic vascular complicationses_ES
dc.subjectEndothelial progenitor cellses_ES
dc.subjectBiomarkerses_ES
dc.titleEndothelial progenitor cells as biomarkers of diabetes-related cardiovascular complicationses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.description.physDesc24 páginases_ES
dc.identifier.doi10.1186/s13287-023-03537-8
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00716/ES/COMPLICACIONES VASCULARES EN DIABETES MELLITUS: APLICACION DE ESTRATEGIAS PROTEOMICAS PARA POTENCIAR EL DESARROLLO DE TERAPIAS MOLECULARES%2FCELULARES ESPECIFICAS PARA CADA PACIENTE/es_ES
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional